血清尿调蛋白与CKD患者死亡、心血管事件及肾衰竭的关联
基于德国CKD(GCKD)队列5143例白人CKD患者,测定基线血清尿调蛋白并随访4年。多变量Cox分析显示,最高四分位血清尿调蛋白者较低四分位者全因死亡、MACE及肾衰竭风险均显著降低。
要点
- 血清尿调蛋白最高四分位者全因死亡风险较低四分位显著降低(HR 0.57)
- 最高四分位者MACE风险较低四分位降低(HR 0.63)
- 最高四分位者肾衰竭风险较低四分位明显降低(HR 0.24)
核心结论
- 在white(白人)CKD患者中,较高血清尿调蛋白独立关联较低的死亡、心血管事件及肾衰竭风险。
研究设计与样本
- 德国CKD(GCKD)队列研究,纳入5143例参与者,测定基线血清尿调蛋白,采用多变量Cox比例风险回归分析。
主要发现
- 随访4年期间335例死亡、417例发生MACE、229例发生肾衰竭。
- 最高四分位较低四分位:死亡HR 0.57(95%CI 0.38–0.87)。
- 最高四分位较低四分位:MACE HR 0.63(95%CI 0.45–0.90)。
- 最高四分位较低四分位:肾衰竭HR 0.24(95%CI 0.10–0.55)。
- 参与者平均年龄60±12岁,60%为男性,平均血清尿调蛋白98±60 ng/ml。
关键数值与推荐
- 平均eGFR 49±18 ml/min per 1.73 m2,78%参与者eGFR<60 ml/min per 1.73 m2。
临床怎么用
- 血清尿调蛋白或可作为CKD患者死亡、心血管事件及肾衰竭风险的生物标志物,用于风险分层。
局限性
- 研究对象为白人CKD患者,结论外推至其他人种需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Uromodulin is exclusively produced by tubular epithelial cells and released into urine and serum. Higher serum uromodulin has been associated with lower risk for kidney failure in Chinese patients with CKD and with lower risk for mortality in the elderly and in patients undergoing coronary angiography. We hypothesized that lower serum uromodulin is associated with mortality, cardiovascular events, and kidney failure in white patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We measured serum uromodulin in 5143 participants enrolled in the German CKD (GCKD) study. The associations of baseline serum uromodulin with all-cause mortality, major adverse cardiovascular events (MACE; a composite of cardiovascular mortality, nonfatal myocardial infarction or stroke, or incident peripheral vascular disease), and kidney failure (dialysis or transplantation) were evaluated using multivariable Cox proportional hazard regression analyses in a cohort study design, adjusting for demographics, eGFR, albuminuria, cardiovascular risk factors, and medication. RESULTS: The mean age of participants was 60±12 years, 60% were male. Mean serum uromodulin concentration was 98±60 ng/ml, eGFR was 49±18 ml/min per 1.73 m2, and 78% had eGFR <60 ml/min per 1.73 m2. Participants in lower serum uromodulin quartiles had lower eGFR and higher albuminuria, prevalence of diabetes, hypertension, coronary artery disease, and more frequent history of stroke at baseline. During a follow-up of 4 years, 335 participants died, 417 developed MACE, and 229 developed kidney failure. In multivariable analysis, the highest serum uromodulin quartile was associated with lower hazard for mortality (hazard ratio [HR], 0.57; 95% CI, 0.38 to 0.87), MACE (HR, 0.63; 95% CI, 0.45 to 0.90), and kidney failure (HR, 0.24; 95% CI, 0.10 to 0.55) compared with the lowest quartile. CONCLUSIONS: Higher serum uromodulin is independently associated with lower risk for mortality, cardiovascular events, and kidney failure in white patients with CKD. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Deutsches Register für Klinische Studien (DRKS; German national database of clinical studies), DRKS00003971.
引用
- Steubl D, Schneider MP, Meiselbach H, et al. Association of Serum Uromodulin with Death, Cardiovascular Events, and Kidney Failure in CKD. Clin J Am Soc Nephrol. 2020. PMID: 32291270. doi:10.2215/CJN.11780919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。